Morgan Stanley Immunity Bio, Inc. Call Options Transaction History
Morgan Stanley
- $1.35 Trillion
- Q3 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding IBRX
# of Institutions
204Shares Held
70MCall Options Held
1.68MPut Options Held
1.31M-
Vanguard Group Inc Valley Forge, PA16.9MShares$44.3 Million0.0% of portfolio
-
Black Rock Inc. New York, NY11.4MShares$29.9 Million0.0% of portfolio
-
State Street Corp Boston, MA8.65MShares$22.7 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA3.85MShares$10.1 Million0.0% of portfolio
-
Bank Of America Corp Charlotte, NC2.07MShares$5.42 Million0.0% of portfolio
About ImmunityBio, Inc.
- Ticker IBRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 400,304,000
- Market Cap $1.05B
- Description
- ImmunityBio, Inc., a clinical-stage biotechnology company, develops therapies and vaccines to treat cancers and infectious diseases. It offers immunotherapy and cell therapy platforms, including antibody cytokine fusion proteins, synthetic immunomodulators, vaccine technologies, natural killer cells, and adaptive (T cell) immune systems. The com...